Gene expression analysis in T2DM and its associated microvascular diabetic complications: focus on risk factor and RAAS pathway
The weight-loss effect of GLP-1RAs also benefits NASH improvement, by reducing appetite and increasing energy expenditure to promote weight loss, thereby indirectly ameliorating NASH
Among the drugs facing loss of exclusivity: Mercks Keytruda, a cancer immunotherapy with over $29 billion in 2024 sales, facing loss of exclusivity in 2028
The Reason: Semaglutide provides biological appetite suppression, whereas intermittent fasting relies on behavioral discipline to manage hunger, which often leads to "overcompensation" (eating too much) during the feeding window
CoQ10 enhances cellular health and helps protect cells from damage
Your body will regain some water weight temporarily, and if you return to pre-treatment eating patterns, weight regain accelerates quickly once appetite rebounds